Medtide Inc.

Medtide opened low and rallied in the morning session, closing up 7.1% at HK$24, driven by the market digesting its H1 profit warning of a 44%-52% decline and its subsidiary's successful FDA pre-license inspection, with the former's negative impact limited and the latter highlighting CDMO compliance advantages. The stock rebounded from an opening of HK$22.5 to an intraday high of HK$24.2, with 42,500 shares traded and a turnover of HK$1.01 million, reflecting moderate activity. Q4 revenue rose 35% YoY to HK$176 million, while net profit surged 1,301% to HK$64 million, with a net margin of 36.5%, yet the H1 profit warning tempers sentiment. The current price is 42.5% below the 52-week high of HK$41.72 but remains above the 20-day MA of HK$21.95. However, the sharp H1 profit decline raises questions about earnings recovery pace.

Medtide surged in the afternoon session, closing 5.72% higher at HKD 23.28, driven by news that its unit Chinese Peptide completed the US FDA pre-license inspection for the Hepcludex API facility, coupled with market expectations ahead of interim results release after the company guided a 44%-52% decline in H1 net profit. The stock traded sideways around HKD 22 in the morning before rallying steadily in the afternoon to hit an intraday high of HKD 23.28, with a full-day range of 6.6%. Recent quarters show revenue growth of 35% and 27% YoY, while net profit surged over 13x YoY, though net profit margin remained stable at 36.5%. The stock still trades 44% below its 52-week high of HKD 41.72 and below the MA60 of HKD 22.2, while YTD it is down 20%. The company's upcoming board meeting to review interim results may provide further clarity.

Medtide surged 6.14% in the morning session to close at HKD 22.82, breaking above MA20 (22.167) and MA60 (22.209), yet still 45.3% below the 52-week high of HKD 41.72 and down 21.85% YTD. The rally was likely driven by news that subsidiary Chinese Peptide completed a US FDA pre-license inspection for its Hepcludex API facility, and the appointment of Ding Lijun as CFO. However, the company guided a 44%-52% YoY decline in H1 profit to RMB 49.4-57.1 million. Q4 2025 net profit surged 1301.31% YoY, operating income rose 102.96%, and net profit margin stood at 36.47%, though growth was partly due to a low base. PE is 13.45, PB 1.84, market cap ~HKD 3.24 billion, with a turnover rate of only 0.03% indicating thin liquidity.

Medtide opened lower and rallied throughout the session, accelerating in the afternoon to close at HKD 20.98, up 5.16%, with an intraday range of approximately 5.9%. The company recently completed a US FDA pre-license inspection of its Hepcludex API facility, appointed Ding Lijun as CFO, and guided for a 44%-52% YoY decline in H1 net profit to RMB 49.4-57.1 million, yet the market appeared to focus on long-term growth drivers. Latest quarterly results showed Q4 revenue rose 35.08% YoY to HKD 175.9 million, while net profit surged 1,301.31% YoY to HKD 64.1 million, with EPS of HKD 0.45. However, the stock remains 49.71% below its 52-week high of HKD 41.72 and trades below both the 20-day MA (HKD 22.87) and 60-day MA (HKD 22.28), with a YTD decline of 28.15%. Current PE stands at 12.36x, PB at 1.7x, and total market cap at HKD 2.97 billion.

泰德医药早盘以 22.0 港元平开即创日内高点，随后震荡回落至 20.96 港元，跌幅约 4.7%，跑输恒指，成为今日港股跌幅居前的中小盘股。公司发布 H1 盈利预警，预计净利润同比下滑 44%-52% 至约 4940 万-5710 万元，与 2025 年全年净利润同比暴增 267% 至 2.17 亿元、以及 Q4 单季 EPS 同比增 1130% 的强劲表现形成鲜明反差，市场迅速消化获利了结压力。同时，公司宣布任命新 CFO，其子公司也完成美国 FDA 对 Hepcludex API 工厂的预批准检查，技术面看，当前股价 20.96 港元远低于 20 日均线 23.17 和 60 日均线 22.34，年初至今已累计下跌 28.2%，且距离 52 周高位 41.72 港元回撤近 50%。不过，公司 PE 仅 12.35 倍，PB 为 1.69 倍，财务基本面仍具一定支撑。